Frederick Hagemeister

Author

The University of Texas MD Anderson Cancer Center

Also Known As

F B Hagemeister, F Hagemeister, F. B. Hagemeister, F. Hagemeister, F.B. Hagemeister, Frederick B Hagemeister, Frederick B. Hagemeister, Frederick Hagemeister

109

Publications

6.4K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Lymphoma Research Foundation Anderson Hospital Memorial Sloan Kettering Cancer Center

About

Frederick Hagemeister is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	30	2.1K
2	Health Sciences	12	12	935
3	Cellular Therapies	2	2	647
4	Public Health	1	1	238
5	Diagnostic Sciences	1	1	100

Frederick Hagemeister

Publications

6.2K

Citations

H-Index

Page 1

	Year	Citations
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas Qing Deng, Guangchun Han, Nahum Puebla‐Osorio, Nature Medicine Lymphoid NeoplasiaRadiation OncologyCell TherapyCancer ImmunosurveillanceMedicine	2020	561
High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine Jorge Romaguera, Luis Fayad, Maria Alma Rodriguez, Journal of Clinical Oncology	2005	557
Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma André Goy, Anas Younes, Peter McLaughlin, Journal of Clinical Oncology	2004	526
Hyper-CVAD Program in Burkitt's-Type Adult Acute Lymphoblastic Leukemia Deborah A. Thomas, Jörge E. Cortes, Susan O’Brien, Journal of Clinical Oncology	1999	271
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma Jorge Romaguera, L. Jeffrey Medeiros, Frederick Hagemeister, Cancer	2003	264
Antibiotic Treatment of Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue: An Uncontrolled Trial Gideon Steinbach, R. Ford, Gary A. Glober, Annals of Internal Medicine	1999	245
Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy. Miguel F Cunha, Marvin L. Meistrich, Lillian M. Fuller, Journal of Clinical Oncology SpermatogenesisFertilityReproductive HealthChemotherapy CyclesGynecology	1984	238
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial Michael Wang, Hun Ju Lee, Hubert H. Chuang, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyPathology	2015	212
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma Constantine S. Tam, Roland L. Bassett, Celina Ledesma, Blood	2009	192
Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma Anas Younes, Stella Kim, Jorge Romaguera, Journal of Clinical Oncology	2012	167

Page 1